Regeneron Pharmaceuticals Inc (NASDAQ:REGN)‘s stock had its “outperform” rating reissued by equities researchers at Leerink Swann in a research note issued on Monday.
A number of other analysts have also issued reports on the stock. BTIG Research reissued a “buy” rating and set a $460.00 target price on shares of Regeneron Pharmaceuticals in a research note on Monday. Canaccord Genuity reissued a “hold” rating and set a $375.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday. CIBC assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Friday. They set a “market perform” rating for the company. Oppenheimer Holdings Inc. assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Thursday. They set a “hold” rating for the company. Finally, Vetr raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $475.44 target price for the company in a research note on Wednesday, March 15th. Fourteen investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $434.97.
Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 0.45% during mid-day trading on Monday, reaching $382.02. 566,392 shares of the company’s stock were exchanged. Regeneron Pharmaceuticals has a one year low of $325.35 and a one year high of $452.96. The firm has a market capitalization of $40.29 billion, a P/E ratio of 49.62 and a beta of 1.44. The company’s 50-day moving average is $371.86 and its 200 day moving average is $379.60.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, February 9th. The biopharmaceutical company reported $3.04 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.03 by $0.01. The firm earned $1.23 billion during the quarter, compared to analyst estimates of $1.30 billion. Regeneron Pharmaceuticals had a net margin of 18.10% and a return on equity of 22.51%. The business’s revenue was up 11.7% on a year-over-year basis. During the same period in the previous year, the firm earned $2.83 earnings per share. Equities analysts predict that Regeneron Pharmaceuticals will post $12.95 earnings per share for the current fiscal year.
var userip;Your IP Address: document.write(userip);
In related news, major shareholder Sanofi acquired 87,298 shares of the business’s stock in a transaction dated Wednesday, January 11th. The shares were purchased at an average price of $369.71 per share, for a total transaction of $32,274,943.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 10.40% of the company’s stock.
Institutional investors have recently bought and sold shares of the stock. WFG Advisors LP increased its position in Regeneron Pharmaceuticals by 12,358.3% in the fourth quarter. WFG Advisors LP now owns 7,475 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 7,415 shares during the period. Alpha Windward LLC increased its position in Regeneron Pharmaceuticals by 11.6% in the third quarter. Alpha Windward LLC now owns 326 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 34 shares during the period. Live Your Vision LLC bought a new position in Regeneron Pharmaceuticals during the third quarter valued at about $157,000. Blenheim Capital Management BV bought a new position in Regeneron Pharmaceuticals during the fourth quarter valued at about $160,000. Finally, Global X Management Co. LLC increased its position in Regeneron Pharmaceuticals by 212.7% in the third quarter. Global X Management Co. LLC now owns 419 shares of the biopharmaceutical company’s stock valued at $168,000 after buying an additional 285 shares during the period. Hedge funds and other institutional investors own 68.83% of the company’s stock.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.